Table 2. Baseline characteristics of the study.
| Categorical variables | Control (n=55) | Medication (n=76) | TEAS (n=47) | F | P |
|---|---|---|---|---|---|
| Age (years, mean ± SD) | 58.8±10.72 | 59.46±8.14 | 58.20±8.30 | 0.282a | 0.755 |
| Course of disease (days) | 10.44±2.28 | 10.4±2.34 | 10.53±2.33 | 1.867a | 0.276 |
| BMI | 26.42±17.02 | 22.31±5.76 | 24.01±6.13 | 1.819a | 0.166 |
| Gender | 1.963b | 0.375 | |||
| Male | 44 | 61 | 33 | ||
| Female | 11 | 15 | 14 | ||
| Age | 0.137b | 0.934 | |||
| <60 years | 25 | 37 | 22 | ||
| ≥60 years | 30 | 39 | 25 | ||
| KPS score | 0.634b | 0.728 | |||
| ≥80 | 54 | 73 | 46 | ||
| <80 | 1 | 3 | 1 | ||
| Type | 0.201b | 0.995 | |||
| Adenocarcinoma | 29 | 38 | 24 | ||
| Squamous carcinoma | 17 | 24 | 14 | ||
| Others | 9 | 14 | 9 | ||
| Stage | 0.054b | 0.973 | |||
| I–III | 51 | 70 | 43 | ||
| IV | 4 | 6 | 4 |
a, F value; b, χ2 value. SD, standard deviation; BMI, body mass index.